Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Saturn Oil & Gas Inc. Announces its First Development of Cardium Wells at Brazeau and Continued Successful Development (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Lineage Cell Therapeutics Inc LCTX

Healthcare Biotechnology
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs. The Company’s programs are based on its cell-based technology platform and associated development and manufacturing capabilities. From this platform, the Company designs, develops, manufactures, and tests specialized human cells with anatomical and... see more

Recent & Breaking News (NYSEAM:LCTX)

BioTime's Subsidiary Cell Cure Neurosciences Ltd. Awarded $1.5 Million Grant from Israel's Office of the Chief Scientist

Business Wire May 13, 2013

BioTime Announces First Quarter 2013 Financial Results and Recent Corporate Accomplishments

Business Wire May 10, 2013

PDL BioPharma Announces First Quarter 2013 Financial Results

PR Newswire May 9, 2013

BioTime and Subsidiary LifeMap Sciences Announce Release of Enhanced LifeMap BioReagents(TM) Portal Offering Additional PureStem(TM) Human Progenitor Cells Including Those for Diabetes Research

Business Wire May 7, 2013

PDL BioPharma Appoints Peter Garcia as Chief Financial Officer

PR Newswire April 30, 2013

LifeMap Sciences, a Subsidiary of BioTime, Announces Release of GeneCards® Version 3.10

Business Wire April 30, 2013

BioTime Announces CFO Succession Plan

Business Wire April 29, 2013

LifeMap Sciences, a Subsidiary of BioTime, Announces Partnership with Appistry

Business Wire April 23, 2013

BioTime Enters into Worldwide License Agreement with UCLA to Develop Therapy for the Treatment of Stroke

Business Wire April 19, 2013

LifeMap Sciences Announces Publication of Research Report Describing the MalaCards Database of Human Diseases

Business Wire April 18, 2013

LifeMap Sciences Adds Products Through Partnership with ProSpec-Tany TechnoGene

Business Wire April 10, 2013

LifeMap Sciences, a Subsidiary of BioTime, Announces Release of LifeMap DiscoveryTM Version 1.1 with Enhanced Therapeutic Discovery and Commercial Utility

Business Wire March 25, 2013

BioTime Announces Fourth Quarter and Fiscal Year End 2012 Financial Results and Recent Corporate Accomplishments

Business Wire March 18, 2013

BioTime to Present at 25th Annual ROTH Conference

Business Wire March 13, 2013

BioTime Appoints Stephen C. Farrell to Board of Directors

Business Wire March 12, 2013

BioTime and Romulus Agree to Accelerate Closing Date for Second Tranche of $5 Million Financing

Business Wire March 7, 2013

Sharp Increase in FDA Drug Approvals a Major Factor in Biotech Industry's Success in 2012

Marketwired March 6, 2013

BioTime and Subsidiary LifeMap Sciences Announce Data Mining Collaboration

Business Wire March 4, 2013

LifeMap Sciences, a Subsidiary of BioTime, Reports Its Databases Currently Utilized by an Estimated Two Million Unique Visitors Annually according to Google Analytics

Business Wire February 11, 2013

BioTime's Subsidiary OncoCyte Corporation Provides an Update on the Development of the Novel Pan-Cancer Diagnostic Product PanC-DxTM

Business Wire January 31, 2013